Zai gets Asia-Pacific license to Entasis' antibiotic combinations

Zai Lab Ltd. (NASDAQ:ZLAB) received an exclusive license to develop and commercialize ETX2514/sulbactam from Entasis Therapeutics Inc. (Waltham, Mass.) in the Asia-Pacific region. The candidate is in Phase II testing to treat severe Acinetobacter baumannii infections.

EXT2514/sulbactam is an injectable combination of ETX2514 -- a class A, C and D beta lactamase (LACTB) inhibitor -- and sulbactam, an antimicrobial. The partners also have an option to collaborate on the development and commercialization of ETX2514 in combination with other active ingredients...